Avalere Essential Voice

Avalere Essential Voice

Download on the App Store

Avalere Essential Voice episodes

  • RSV Prevention, Part IV: Immunocompromised Populations

    Tune into the fourth episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss the evolving landscape of RSV preventive products and considerations for both pediatric and adult populations with chronic medical conditions.

    13 min
  • RSV Prevention, Part I: Pediatric Monoclonal Antibodies

    Tune into the first episode in our video series focused on Respiratory Syncytial Virus (RSV) prevention. In this segment, Avalere experts discuss how innovative offerings in the pediatric RSV immunization market will fit within the continuum of care and how the RSV preventive market will grow in the upcoming years.

    9 min
  • NCDs, Part III: Agency Mandates, Decisions, Coverage, and Access

    Tune into the third episode in the Avalere Health Essential Voice podcast series focused on Agency decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs) by considering how potential policy and market catalysts 3 to 5 years out may help stakeholders think through opportunities and risks at key decision points ranging from early in development to implications for Part D.

    10 min
  • NCDs, Part II: Evidence Development to Fulfill CED Requirements

    Tune into the second episode in the Avalere Health Essential Voice podcast series focused on the how CMS and Medicare coverage decisions define patient access. In this segment, our experts continue the conversation around national coverage determinations (NCDs)that have coverage with evidence development (CED) requirements, how FDA and CMS's evidence questions can be complimentary, and the ways in which manufacturer evidence generation plans can address those goals, using the NCD on monoclonal antibodies for Alzheimer's disease as an example.

    21 min
  • NCDs, Part I: Overview of NCDs, CED, and Potential Access Barriers

    Tune into the first episode in the Avalere Health Essential Voice podcast series focused on how CMS and Medicare coverage decisions define patient access. In this segment, our Market Access experts discuss national coverage determinations (NCDs), specifically those with coverage with evidence development (CED), their impacts to patient access, and considerations for life sciences companies.

    14 min

About Avalere Essential Voice

From the publisher's feed

Twenty years ago, Avalere set out to be the essential voice in improving healthcare. Rest your eyes or use your commute time to listen to our experts discuss the hot topics that you need to track.